Sucralfate: worldwide experience in recurrence therapy

Abstract

International studies have shown sucralfate to be a safe and effective short- and long-term treatment for patients with peptic ulcer. Available data suggest that the more convenient dosage schedule of 2 g b.i.d. may be preferable to the conventional 1 g q.i.d. regimen for short-term duodenal ulcer healing, and that a maintenance dose of 2 g at night may be appropriate in the long-term management of patients with gastric or duodenal ulcer disease. Smoking has no adverse effect on healing in sucralfate-treated duodenal ulcer patients, and sucralfate granules do not appear to be more effective than tablets in ulcer healing.